Episode 216: Update on Broluciziumab Safety Including HAWK/HARRIER Phase 3 Trial Data

Drs. Thomas Albini, Aleksandra Rachitskaya, and Charles Wykoff of the Vit-Buckle Society join for a group discussion of brolucizimab safety data including a discussion of idiopathic ocular inflammation and arterial occlusions from HAWK/HARRIER Phase 3 trials, post-market reports of adverse events, and approach to utilizing brolucizumab going forward.

Financial Disclosures:Dr. Sridhar: Consultant for Alcon, Alimera, Oxurion, and Regeneron
Dr. Albini: Consultant for Bausch and Lomb
Dr. Rachitskaya: Consultant for Alcon, Allergan, Zeiss, Speaker for Novartis, Research funding from Genentech, Novartis, Second Sight
Dr. Wykoff: Consultant/Speaker/Research Funding from Allergan, Genentech, Novartis and Regeneron, Consultant and Research Funding from Bayer, Roche

You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audio&sub=ONE.ContentTypes.Audio.